9 completed, 9 terminated, 6 recruiting, 4 unknown. 16 Phase 1, 16 Phase 2, 5 Phase 3, 3 Not applicable, 1 Phase 4.
Follow Acute Graft Versus Host Disease: new trials by email Literature Review of Acute Graft Versus Host Disease trials Research Report on Acute Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation Human amniotic epithelial stem cells（hAESCs）, placebo (cell preservation solution) - Acute Graft Versus Host Disease | Phase 1 | Withdrawn | Nanfang Hospital, Southern Medical University | 2026-06-01 | 2026-04-16 | |
| Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease Dental Cleaning, Dental Plaque sampling - Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 45 | 2026-05-12 | 2026-10-21 |
| First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) Gecacitinib (also known as Jaktinib) combined glucocorticoids - Acute Graft Versus Host Disease | Phase 1 / Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 35 | 2025-12-03 | 2025-12-16 |
| Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT Time of umbilical cord blood infusion - Acute Graft Versus Host Disease | Phase 3 | Recruiting | Anhui Provincial Hospital | 134 | 2025-07-11 | 2025-12-23 |
| Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment Human chorionic gonadotropin (hCG), Prednisone, Dexamethasone - Acute Graft Versus Host Disease | Phase 2 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 20 | 2025-02-01 | 2025-04-03 |
| Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases Basiliximab - Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 39 | 2024-07-01 | 2024-06-28 |
| Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD CD25 antibody combined glucocorticoid as first-line treatment - Acute Graft Versus Host Disease | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2024-07-01 | 2024-06-25 |
| Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study Serum metabolomics sequencing - Stem Cell Transplant Complications, Acute Graft Versus Host Disease | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 500 | 2024-05-01 | 2024-04-26 | |
| Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation Fecal Microbiota Transplantation Capsule, Placebo - Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 157 | 2023-12-12 | 2026-10-20 |
| Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease Fecal Microbiota Transplantation Capsule - Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2023-09-01 | 2023-09-22 | |
| Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD MTX, Corticosteroid - Acute Graft Versus Host Disease | Phase 3 | Recruiting | Peking University People's Hospital | 218 | 2023-08-03 | 2025-06-03 |
| Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies Cholestyramine, Leflunomide, Steroid Therapy - Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm | Phase 1 | Recruiting | City of Hope Medical Center | 18 | 2023-06-16 | 2026-07-08 |
| Safety and Clinical Activity of Itolizumab in aGVHD Itolizumab, Methylprednisolone - Acute Graft Versus Host Disease | Phase 1 | Unknown | Biotech Pharmaceutical Co., Ltd. | 44 | 2023-05-19 | 2023-05-25 |
| Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD BRD4 Inhibitor PLX51107 - Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease | Phase 1 / Phase 2 | Terminated | Hannah Choe, MD | 2 | 2022-04-19 | 2025-01-28 |
| MTX and Steroid for III-IV aGVHD Treatment Methotrexate - Acute Graft Versus Host Disease | Phase 2 | Unknown | Peking University People's Hospital | 30 | 2021-04-21 | 2022-04-20 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Efprezimod alfa, Placebo, Methotrexate - Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | Phase 3 | Terminated | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 11 | 2021-01-05 | 2023-02-08 |
| ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients ApoGraft - Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant | Phase 1 | Terminated | Washington University School of Medicine | 4 | 2020-12-16 | 2023-05-19 |
| Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease Ruxolitinib - Acute Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 45 | 2019-02-21 | 2025-05-04 |
| Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease MSCTC-0010 Dose Escalation - Acute Graft Versus Host Disease | Phase 1 | Completed | University of Kansas Medical Center | 24 | 2018-07-09 | 2026-02-24 |
| Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Lactobacillus plantarum strain 299, Lactobacillus plantarum strain 299v - Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 3 | Active not recruiting | Children's Oncology Group | 173 | 2018-04-30 | 2025-10-06 |
Showing 20 of 36. Sign in to see all of them.
Graft vs Host Disease (6) · Bronchiolitis Obliterans Syndrome (3) · Acute Kidney Injury (1) · Cardiovascular Diseases (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Immune System Diseases (10) · Bronchial Diseases (3) · Bronchiolitis (3) · Bronchiolitis Obliterans (3) · Bronchitis (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Lung Diseases (3) · Lung Diseases, Obstructive (3) · Neoplasms (3) · Organizing Pneumonia (3) · Respiratory Tract Diseases (3) · Graft vs Host Disease (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2)
Methotrexate (3) · Methylprednisolone (3) · Adrenal Cortex Hormones (2) · Fecal Microbiota Transplantation (2) · Methylprednisolone Hemisuccinate (2) · Parturition (2) · Prednisone (2) · Tacrolimus (2) · Basiliximab (1) · Budesonide (1) · Cholestyramine Resin (1) · Chorionic Gonadotropin (1) · Dexamethasone (1) · Etanercept (1) · Exercise Test (1)
Anhui Provincial Hospital (2) · Fred Hutchinson Cancer Center (2) · M.D. Anderson Cancer Center (2) · Peking University People's Hospital (2) · AbGenomics B.V Taiwan Branch (1) · Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Astex Pharmaceuticals, Inc. (1) · Biotech Pharmaceutical Co., Ltd. (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Emory University (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · First Affiliated Hospital of Zhejiang University (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (20) · China (6) · Belgium (2) · Canada (2) · Israel (2) · Netherlands (2) · Spain (2) · Denmark (1) · France (1) · Italy (1) · Japan (1) · Mexico (1) · South Korea (1)
Xiaoyu Zhu, Ph.D (2) · An T Ngo-Huang (1) · Anton V Schattenberg,, MD, PhD, (1) · Armin Rashidi (1) · Armin Rashidi, MD, PhD (1) · Claudio Anasetti, MD (1) · Erlie Jiang (1) · Everett Meyer, MD (1) · Gordon Phillips (1) · Grace Aldrovandi (1) · Hannah Choe, MD (1) · James L. Gajewski, MD (1) · John E Levine, MD (1) · Joseph McGuirk, DO (1) · Mark Schroeder, M.D. (1)
PMID 22533831, PMID 22689677, PMID 24892263, PMID 32071418, PMID 32160294, PMID 32320566, PMID 33278131, PMID 36189324, PMID 37235690, PMID 38775157, PMID 39046767, PMID 39093227, PMID 39863610
2014 (1), 2016 (1), 2018 (1), P30CA012197 (1), P30CA033572 (1), R01CA201788 (1), R01CA252469 (1), UG1CA189955 (1)